Cryoport, Inc. (Cryoport) operates as a global leader in integrated temperature-controlled supply chain solutions for the life sciences industry, with a strong focus on supporting the Cell and Gene Therapy market (CGT).
With over 50 strategic locations covering the Americas, EMEA (Europe, the Middle East, and Africa), and APAC (Asia Pacific), Cryoport's global platform provides mission-critical bio-logistics, bio-storage, bio-processing, and cryogenic systems to over 3,000 customers worldwide....
Cryoport, Inc. (Cryoport) operates as a global leader in integrated temperature-controlled supply chain solutions for the life sciences industry, with a strong focus on supporting the Cell and Gene Therapy market (CGT).
With over 50 strategic locations covering the Americas, EMEA (Europe, the Middle East, and Africa), and APAC (Asia Pacific), Cryoport's global platform provides mission-critical bio-logistics, bio-storage, bio-processing, and cryogenic systems to over 3,000 customers worldwide. The company's platform of solutions and services, together with its global team of over 1,100 dedicated colleagues, delivers a unique combination of innovative supply chain technologies and services through its industry-leading brands, including Cryoport Systems, MVE Biological Solutions (MVE), CRYOPDP, and CRYOGENE.
The company's broad array of products and services are designed to mitigate risks and ensure the safe and reliable storage and delivery of critical therapies and other high-value biologic materials. The company supports the entire continuum from biomaterial collection to final delivery, enabling the future of medicine.
The company has a global presence through its directly operated global supply chain centers, logistics centers, and depots, biostorage/bioservices, and cryoprocessing centers. The company has partner networks in the Americas, EMEA (Europe, the Middle East, and Africa), and APAC (Asia-Pacific) regions. In addition, its MVE Biological Solutions business unit operates three cryogenic systems manufacturing centers in the U.S. (2) and China (1).
Markets
The company is an integrated temperature-controlled supply chain solutions and has developed industry-leading products and services that seamlessly integrate into a comprehensive supply chain platform supporting the life sciences market, including the biopharma/pharma, animal health, and reproductive medicine markets.
In the biopharmaceutical space, the company has concentrated on emerging fields, particularly cell and gene therapies. These therapies are among the most sensitive pharmaceutical products, requiring stringent distribution standards supported by informatics.
Cryoport Products and Services
The company continuously works to expand and improve its products and services across the life sciences supply chain with innovative, technology-centric solutions.
The company’s suite of market leading products and services include, but are not limited, to the following:
Cryoport Express Shippers: Cryoport Express Shippers range from liquid nitrogen dry vapor shippers (-150 degree Celsius) to the company’s C3 Shippers (2-8 degree Celsius), which are powered by phase-change materials. The Cryoport Express Shippers are precision-engineered assemblies that are reliable, cost-effective, and reusable or recyclable. The company’s liquid nitrogen dry vapor Cryoport Express Shippers utilize an innovative application of ‘dry vapor’ liquid nitrogen technology, and most often, include a SmartPak Condition Monitoring System. Cryoport Express Shippers meet IATA (International Air Transport Association) requirements for transport, including Class 6.2 infectious substances, are also ISTA (International Safe Transit Association) Transit Tested certified and carry the CE (Conformite Europeenne) mark demonstrating conformance with European Union (EU) health, safety, and environmental protection standards.
Cryoport ELITE Shippers - The first product, in this high-performance line of Cryoport ELITE Shippers, is a best-in-class -80°C shipper that has superior temperature management properties, as well as incorporating next generation protection, handling, and data collection and management systems including the company’s SmartPak Condition Monitoring System. The Cryoport ELITE -80°C Gene Therapy Shipper was developed in conjunction with one of the leaders in the gene therapy space for clinical and commercial gene therapy distribution and was launched during the second quarter of 2023.
Cryoport Express Cryogenic HV3 Shipping System (HV3) – During the first quarter of 2025, the company introduced the HV3 which provides optimized hold times for interior payloads, improved storage efficiency, and full compliance with airline requirements, including narrow bodied aircraft. Tailored to meet the specific needs of advanced therapies, the HV3 ensures enhanced payload security, superior temperature control, payload integrity and extended temperature stability at cryogenic temperatures. Its innovative enclosure design and configuration eliminates the need for palletization on narrow-bodied aircraft, ensuring compliance with regional carriers and reducing flight rejections and delays. This enhancement also opens additional shipping lanes, making it easier for life-saving therapies to reach more remote destinations. Designed with the end-user in mind, the HV3 features robust wheels and an integrated, front-facing handle to ensure easy mobility at any stage of transit.
Smartpak II Condition Monitoring System and Tec4Med – Cryoport’s Smartpak II Condition Monitoring System (‘Smartpak II’) delivers comprehensive visibility into the location and conditions of valuable materials throughout the entire shipment process. The system also provides critical data to validate that sample integrity is maintained during transit. The Smartpak II monitors key parameters, including location, temperature, shock, orientation, and pressure, with immediate alerts enabling swift intervention when necessary. Seamlessly integrating with the company’s Cryoportal Logistics Management Platform, the Smartpak II provides visibility of near real-time reporting, combining condition monitoring, logistics management, and shipper qualification performance into a single data stream for enhanced oversight and reliability.
The company acquired Tec4Med, a company providing cold-chain packaging temperature and location monitoring, warehouse monitoring as well as bench top monitoring for laboratories and research facilities during the fourth quarter of 2023. Technological innovations from Tec4Med include:
The SmartHub is an intelligent Beacon-Gateway Monitoring System and can be integrated into any logistics process at box, pallet, container, truck or warehouse level. In doing so, it enables full supply chain visibility in real-time.
The CryoBeacon serves as an intelligent temperature and humidity data logger with advanced capabilities. It effectively records all data internally and offers two methods of data retrieval: manual access through the Tec4App and automated retrieval via the SmartHub gateway. Designed for multiple applications, the CryoBeacon can be utilized repeatedly for different shipments.
With its solutions, the company’s clients have the peace of mind that comes with knowing exactly where their shipments are at all times, ensuring that they can deliver high-quality pharmaceutical products to their clients with confidence. By adopting risk mitigation measures, the company's clients can proactively identify and address potential threats to their operations and supply chain. This saves valuable resources that can be redirected toward other critical areas of their business, allowing them to operate more efficiently and effectively. Through Tec4Med technology, they can optimize their operations and build a more resilient business for the long term. The company intends to leverage Tec4Med technology across many of Cryoport’s products and services in the coming years.
Cryoport Accessories – The company’s purpose-built accessories are integral to its comprehensive integrated temperature-controlled supply chain solutions. Designed to seamlessly integrate with its advanced shipping systems, the company’s accessories safeguard materials and minimize risks at every stage of s their journey—spanning critical phases of development and manufacturing. From its proprietary Safepak and SoftRack Systems to specialized labels, cassette racks and cryovial boxes, each accessory is meticulously engineered to help ensure security and preserve the integrity of critical therapies and biomaterials throughout the supply chain. The company’s accessories include: Safepak System 1800, Safepak XL, Soft Rack, Cryostrap, and Cryoport Elite Ultra Cold Shipping Systems' Payload Holding System among others.
Cryoport BioStorage/Bioservices – The company offers biostorage and bioservices solutions through two of its business units, CRYOGENE and Cryoport Systems.
CRYOGENE - Acquired in 2019, CRYOGENE provides biostorage solutions primarily for the provision of pre-clinical temperature-controlled biological materials management services to the life sciences industry. With a focus on pre-clinical commodities, it is one of the medical research industry’s leading biorepository, focusing on the secure storage of biological specimens and associated supplies. Utilizing the latest freezer and cryogenic storage technologies and computer inventory control software, CRYOGENE can cost-effectively fulfill life sciences bio-storage and distribution requirements. The company’s services include comprehensive specimen storage, processing, collection, and retrieval at its CRYOGENE operations in Houston, Texas, and San Antonio, Texas, the latter which was opened during the first quarter of 2024. Both facilities are FDA registered for storage and distribution and compliant with Current Good Tissue Practice (CGTP), Current Good Manufacturing Practices (cGMP), and the American Association of Tissue Banks (AATB). In January 2025, the company announced a strategic partnership with the Moffitt Cancer Center (MCC), a leading National Cancer Institute-designated comprehensive cancer center, whereby CRYOGENE will establish a state-of-the-art biorepository center in conjunction with MCC’s planned 775-acre global innovation life sciences campus in Pasco County, Florida. CRYOGENE facilities in Florida are expected to be fully validated and open during the second half of 2026.
Cryoport Systems Bioservices - In June 2022, the company launched its first two Global Supply Chain Centers in Houston, Texas and Morris Plains, New Jersey. These state-of-the-art facilities combine its existing logistics processes and capabilities with the company’s BioServices infrastructure – all under one roof, as Cryoport Systems’ Global Supply Chain Center Network. These Global Supply Chain Centers offer a new and fully integrated approach designed to support cell and gene therapies including comprehensive controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person (QP) drug product release, along with advanced BioLogistics. Cryoport Systems’ BioServices facilities in the United States are registered with the FDA as Tissue Establishments, complying with FDA CFR 1271.10. In April 2022, the company acquired Cell&Co BioServices in Clermont-Ferrand, France with additional bioservices operations in Pont-du-Château, France to accelerate the setup of its BioServices capabilities in the EMEA region. The company’s sites are ISO 9001 and ISO 20387 accredited and all GMP IT systems are 21CFR Part 11, and GAMP-5 compliant (both the U.S. and EU).
Cryopreservation Services (IntegriCell) - In conjunction with its acquisition of Cell Matters in July 2022, the company developed its IntegriCell service platform. The IntegriCell platform is a fully standardized, scalable apheresis cryo-processing platform that can be expanded on a global basis. The platform services include apheresis/leukapheresis collection via partners, Cryoshuttle transportation services, cryo-process optimization, cryopreservation services, and BioServices. The company has recently opened its first two facilities in Liège, Belgium, and Houston, Texas. These two facilities became operational during the fourth quarter of 2024.
Cryoport Consulting Services – Cryoport Consulting Services functions in an expert advisory capacity to offer solutions to address risk factors present in temperature-controlled supply chain and logistics. To develop tailored scalable solutions, the company's cross-functional team collaborates with its clients to understand their supply chain, logistics, time, shipper, and packaging concerns. Cryoport Consulting Services employs a structured approach to managing, executing, and developing risk mitigation plans. The company's clients benefit from its quality-driven processes and solutions delivered by its high integrity team, leveraging industry-standard best practices and years of experience partnering with leading life science companies from early clinical through post-commercialization. Service solutions range from comprehensive physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing user-friendly custom packaging solutions focused on the challenges unique to its life science clients.
CRYOPDP Temperature-controlled Logistics - CRYOPDP is a premier global specialty courier dedicated to the life sciences industry that the company acquired in 2020. CRYOPDP operates with expertise in an exhaustive range of temperature-controlled logistics services, including temperature-controlled packaging and premium transport solutions. In recent years, CRYOPDP further expanded organically, as well as through acquisitions in Ireland, Belgium, Spain, Australia, and the United States. Through the acquisition of CRYOPDP, the company expanded its global presence and provided Cryoport with in-house specialty courier capabilities to complement its network of global partners.
MVE Biological Solutions - The acquisition of MVE Biological Solutions in 2020 enabled Cryoport to become the leading global provider of cryogenic systems and solutions. MVE Biological Solutions supplies cryogenic systems globally and is an important part of the company's global supply chain platform. With its long history of producing the most reliable, highest quality products in the industry, it has set the standard for the manufacture of cryogenic systems, including freezer and shipper solutions used for the storage and/or distribution of critical biological material, for 60 years. Two examples of MVE Biological Solutions' advanced development achievements are:
MVE Biological Solutions’ Fusion Cryogenic System – The MVE Fusion is a self-sustaining cryogenic freezer. The MVE Fusion can operate as a stand-alone unit, requiring no on-going liquid nitrogen supply or connection to an external liquid nitrogen source. Fusion cryogenic freezers are a perfect solution for remote geographic locations, isolated laboratories, high elevation facilities, or facilities without existing liquid nitrogen infrastructure.
MVE Biological Solutions’ Vario Cryogenic System – is an innovative cryogenic freezer system that can support temperatures anywhere between -20°C and -150°C. In addition to providing greater flexibility, the Vario series of cryogenic freezer systems provide effective and consistent temperature profiles with less than 1% of the power consumption and a 70% reduction in overall operating cost savings compared to traditional mechanical freezers.
Segments
The company operates through two segments: Life Sciences Services and Life Sciences Products.
The company’s Life Sciences Services which provide temperature-controlled logistics and cryogenic biostorage within the life science industry through direct sales. Revenues from this segment include an immaterial amount of product revenues.
The company’s Life Sciences Products segment manufactures and sells cryogenic freezers, cryogenic dewars and accessories within the life science industry through direct sales or a distribution network. Revenues from this reportable segment are exclusively life sciences product revenues.
Customer Types
The company’s major customer types include biotechnology and pharmaceutical companies, contract research organizations, contract development & manufacturing companies, central laboratories, fertility clinics, animal health companies, universities & research facilities.
Sales and Marketing
The company serves clients across the life sciences industry, with a particular focus on the rapidly evolving Cell and Gene Therapy market. Its global sales and marketing efforts are centered on addressing each customer’s unique challenges and anticipating their future needs through its specialized temperature-controlled supply chain solutions. The company's marketing teams create and execute targeted digital campaigns that align with its commercial strategy, showcasing its portfolio of solutions and capabilities. These initiatives are designed to fuel business development, program management, and consulting activities, while also enhancing awareness of its advanced temperature-controlled supply chain solutions.
Patents
As of December 31, 2024, the company owned approximately 95 issued patents and had more than 140 pending patent applications throughout the world.
Government Regulation
The company’s Cryoport Express and ELITE Shippers meet Packing Instructions 602 and 650 and are certified for the shipment of Class 6.2 Dangerous Goods per the requirements of the ICAO Technical Instructions for the Safe Transport of Dangerous Goods by Air and IATA. The company’s present and planned future versions of the Cryoport SmartPak Condition Monitoring Systems will likely be subject to regulation by the Federal Aviation Administration (FAA), Federal Communications Commission (FCC), FDA, IATA and possibly other agencies which may be difficult to determine on a global basis. Additionally, the company’s Chain of Compliance processes comply fully with ISO 21973 guidelines.
The company’s MVE Biological Solutions cryogenic stainless-steel freezers and aluminum dewars are certified to the Medical Device Directive (MDD) in the EU. MVE is compliant with current Good Manufacturing Practices (GMP) regulations which are enforced by the FDA through registration and audit of compliance with 21 CFR Part 820 and GMP. This FDA registration and product listing is in addition to MVE’s existing ISO 13485 certification.
The company is also subject to GMED, which is an international reference body in the certification of health care and medical devices quality management systems under ISO 9001, NF EN, and ISO 13485. As such, the company is subject to audits by a Medical Device Single Audit Program (MDSAP) auditing organization. Cryoport’s cryogenic biostorage facilities are routinely inspected by the FDA and The Foundation for the Accreditation of Cellular Therapy (FACT) to confirm regulatory compliance to industry requirements related to drug applications, filings, and maintenance of various cryogenically stored materials.
Cryoport’s advanced integrated temperature-controlled supply chain solutions platform is designed to support the global distribution of high-value commercial biologic and cell-based products and therapies regulated by the United States Food and Drug Administration (FDA), the European Medicines Association (EMA) and other international regulatory bodies. Cryoport’s solutions are also relied upon for the support of pre-clinical, clinical trials, Investigational New Drug Applications (IND), Biologics License Applications (BLA), and New Drug Applications (NDA) with the FDA, as well as global clinical trials initiated in other geographies, where strict regulatory compliance and quality assurance is mandated.
History
CryoPort, Inc. was founded in 1999.
